Biological characterization and preliminary crystallization: A step towards the use of Novel Allium sativum Protease inhibitor as a potential therapeutic drug

Q4 Pharmacology, Toxicology and Pharmaceutics Current Enzyme Inhibition Pub Date : 2021-08-09 DOI:10.2174/1573408017666210809104744
Tooba Naz Shamsi, Sumbul Afreen, Romana Parveen, Manish Kumar, T. Fatma, S. Fatima
{"title":"Biological characterization and preliminary crystallization: A step towards the use of Novel Allium sativum Protease inhibitor as a potential therapeutic drug","authors":"Tooba Naz Shamsi, Sumbul Afreen, Romana Parveen, Manish Kumar, T. Fatma, S. Fatima","doi":"10.2174/1573408017666210809104744","DOIUrl":null,"url":null,"abstract":"\n\nGarlic, being a well-known medicinal plant is the most commonly used culinary spice worldwide. Investigation of protease inhibitor isolated from garlic leads to a promising contender in pharmacognostic and pharmacological studies.\n\n\n\nProtease Inhibitor (PI) from 'garlic' (Allium sativum) was analyzed for its biological role as an antioxidant, antimicrobial, and anti-inflammatory agent. \n\n\n\nAntioxidant activity was evaluated using ferric ion reducing antioxidant power (FRAP) and 2, 2-diphenyl-1-picrylhydrazyl (DPPH) assays. The anti-inflammatory activity was assessed using trypsin inhibitory assay and heat-induced albumin denaturation method. The antimicrobial activity was examined in broth against E. coli and B. Subtilis. The crystallization was setup using the hanging drop method.\n\n\n\nASPI showed DPPH radical scavenging with IC50 values 561±0.337 µg/ml. Also, ASPI showed the highest value of 0.699±0.009 mM at 1000 μg/ml and the lowest i.e. 0.181±0.006 mM at 100 μg/ml in FRAP assay. Ascorbic acid was taken as standard in both cases. ASPI showed IC50 values of 651±0.532 μg/ml and ~657±1.802 μg/ml respectively. The antibacterial role of ASPI was testified and results showed maximum inhibition against E. coli (ATCC 25922) i.e., 87.8 ±0.602% but no inhibition against B. subtilis (MTCC 736). Cuboidal shaped crystals of the ASPI were obtained in 4-6 weeks using 0.2M calcium chloride dihydrate, 0.1M sodium acetate trihydrate, 20 % isopropanol.\n\n\n\nASPI has tremendous potential for the development of suitable drugs in pharmaceutical industries against diseases due to the generation of reactive oxygen species and cancer. The cuboidal crystals were obtained which is the first study in the context of crystallization of ASPI to date.\n","PeriodicalId":35405,"journal":{"name":"Current Enzyme Inhibition","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Enzyme Inhibition","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1573408017666210809104744","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Garlic, being a well-known medicinal plant is the most commonly used culinary spice worldwide. Investigation of protease inhibitor isolated from garlic leads to a promising contender in pharmacognostic and pharmacological studies. Protease Inhibitor (PI) from 'garlic' (Allium sativum) was analyzed for its biological role as an antioxidant, antimicrobial, and anti-inflammatory agent. Antioxidant activity was evaluated using ferric ion reducing antioxidant power (FRAP) and 2, 2-diphenyl-1-picrylhydrazyl (DPPH) assays. The anti-inflammatory activity was assessed using trypsin inhibitory assay and heat-induced albumin denaturation method. The antimicrobial activity was examined in broth against E. coli and B. Subtilis. The crystallization was setup using the hanging drop method. ASPI showed DPPH radical scavenging with IC50 values 561±0.337 µg/ml. Also, ASPI showed the highest value of 0.699±0.009 mM at 1000 μg/ml and the lowest i.e. 0.181±0.006 mM at 100 μg/ml in FRAP assay. Ascorbic acid was taken as standard in both cases. ASPI showed IC50 values of 651±0.532 μg/ml and ~657±1.802 μg/ml respectively. The antibacterial role of ASPI was testified and results showed maximum inhibition against E. coli (ATCC 25922) i.e., 87.8 ±0.602% but no inhibition against B. subtilis (MTCC 736). Cuboidal shaped crystals of the ASPI were obtained in 4-6 weeks using 0.2M calcium chloride dihydrate, 0.1M sodium acetate trihydrate, 20 % isopropanol. ASPI has tremendous potential for the development of suitable drugs in pharmaceutical industries against diseases due to the generation of reactive oxygen species and cancer. The cuboidal crystals were obtained which is the first study in the context of crystallization of ASPI to date.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
生物学特性和初步结晶:利用新型大蒜蛋白酶抑制剂作为潜在治疗药物的一步
大蒜是一种著名的药用植物,是世界上最常用的烹饪香料。从大蒜中分离得到的蛋白酶抑制剂在生药学和药理学研究中具有广阔的应用前景。从大蒜(Allium sativum)中提取蛋白酶抑制剂(PI),分析其作为抗氧化、抗菌和抗炎剂的生物学作用。采用铁离子还原抗氧化能力(FRAP)和2,2 -二苯基-1-苦味酰肼(DPPH)测定抗氧化活性。采用胰蛋白酶抑制法和热诱导白蛋白变性法测定其抗炎活性。在肉汤中对大肠杆菌和枯草芽孢杆菌进行了抑菌活性测定。采用吊滴法进行结晶设置。ASPI对DPPH自由基具有清除作用,IC50值为561±0.337µg/ml。在1000 μg/ml时,ASPI最高为0.699±0.009 mM;在100 μg/ml时,ASPI最低为0.181±0.006 mM。在这两种情况下都以抗坏血酸为标准。ASPI的IC50值分别为651±0.532 μg/ml和~657±1.802 μg/ml。结果表明,ASPI对大肠杆菌(ATCC 25922)的抑菌率为87.8±0.602%,对枯草芽孢杆菌(MTCC 736)无抑制作用。采用0.2M二水合氯化钙、0.1M三水合乙酸钠、20%异丙醇,在4 ~ 6周内获得立方晶体。ASPI在制药行业针对活性氧产生的疾病和癌症的合适药物的开发方面具有巨大的潜力。获得了立方晶体,这是迄今为止在ASPI结晶方面的首次研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Current Enzyme Inhibition
Current Enzyme Inhibition Pharmacology, Toxicology and Pharmaceutics-Drug Discovery
CiteScore
1.30
自引率
0.00%
发文量
30
期刊介绍: Current Enzyme Inhibition aims to publish all the latest and outstanding developments in enzyme inhibition studies with regards to the mechanisms of inhibitory processes of enzymes, recognition of active sites, and the discovery of agonists and antagonists, leading to the design and development of new drugs of significant therapeutic value. Each issue contains a series of timely, in-depth reviews written by leaders in the field, covering a range of enzymes that can be exploited for drug development. Current Enzyme Inhibition is an essential journal for every pharmaceutical and medicinal chemist who wishes to have up-to-date knowledge about each and every development in the study of enzyme inhibition.
期刊最新文献
Apocynaceae as a Potential Source for Acetylcholinesterase Inhibition in Symptomatic Regulation and Management of Alzheimer's Disease Inhibition of Perforin: A Potential Therapeutic Approach against Human Ailments Molecular Docking as a Method to Identify Prospective Compounds from Ocimum sanctum with Anti-Candidal Properties Design of Cyclobut-3-Ene-1,2 Dione Derivatives as Anti-tubercular Agents Enzyme Inhibition in Managing Cardiovascular Diseases
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1